Term
|
Definition
| can take up to a year to see clinical effects, eye exams to check for retinal damage |
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibits dihydrofolate reductase, increasing adenosine which inhibits lymphocyte proliferation; supplement with folate |
|
|
Term
|
Definition
| symptomatic relief, may be used intraarticularly |
|
|
Term
|
Definition
| can be used with NSAID or ASA and low dose corticoids; inhibits Cox2 and some leukotrienes and blocks pyrimidine synthesis/ tyrkinase |
|
|
Term
|
Definition
| leflunomide, methotrexate |
|
|
Term
|
Definition
| human TNFalpha receptor Fc fusion protein,SQ, immunosupression and injection site reactions |
|
|
Term
|
Definition
| chimaric mouse mAB specific for TNF, IV infusion, can develop antinuclear Abs |
|
|
Term
|
Definition
| human mAB specific for TNF, SQ, think immunosuppression, black box TB infection relapse |
|
|
Term
|
Definition
| pegylated fab fragment (prolonged circulation, protected against enzematic degradation, slower renal filtration and improved stability) warning; infection risk, cancer onset, get immunizations early and avoid live vaccines |
|
|
Term
|
Definition
| human-derived mAB against TNF alpha, SQ, same contraindications, seek medical attention if there is any sign of infection |
|
|
Term
|
Definition
| IL-1 receptor inhibitor, blocks inflammatory signaling (monocyte/macrophage activation, fibroblast proliferation, and chondrocyte activation) |
|
|
Term
|
Definition
| recombinant humanized mAB binds IL6 receptor, increased risk of serious infections |
|
|
Term
|
Definition
| costimulation modulator the blocks signal 2 of T cell activation, weight based dosing |
|
|
Term
|
Definition
| anti-CD20 specific for B cells mAB, B cell apoptosis, infusion rxns and pancytopenia |
|
|
